… thrombosis, proximal This review focuses on the long-term treatment of leg deep vein
thrombosis (DVT) and pulmonary embolism (PE) and does not include arm DVT or venous …

… rivaroxaban 20 mg, rivaroxaban 10 mg, and aspirin 100 mg for extended treatment of venous
thromboembolism in patients who had completed 6 to 12 months of anticoagulant therapy. …

… of anticoagulant therapy, the need for extended treatment is usually determined by balancing
the risk of recurrence if treatment is stopped against the risk of bleeding if treatment is …

… These new findings on extended therapy suggest the possibility of anticoagulation regimens
… VTE characteristics, with a shift of the risk-benefit balance in favour of extended treatment. …

… Anticoagulation therapy (AT) remains the mainstay of treatment for VTE. Clinical guidelines
… deep vein thrombosis (DVT) or pulmonary embolism (PE), with consideration of long-term, …

… Rivaroxaban is the world’s first oral inhibitor of factor Xa. It is used to prevent and treat venous
thromboembolism and prevent stroke or systemic embolism in atrial fibrillation [19]. It has …

… anticoagulation, estimates from this study could be used to determine the net clinical
benefit of extended treatment to guide long‐term management of unprovoked VTE. …

… The results of the COMPASS LTOLE study indicate that in patients with chronic CAD and/or
PAD, extended treatment with the combination of rivaroxaban 2.5 mg twice daily and aspirin …

… of symptomatic venous thromboembolism (VTE) … treatment with rivaroxaban plus aspirin
would be superior to use of neither rivaroxaban nor aspirin in preventing major thromboembolic …

… treatment durations in these trials ranged from 4 weeks to 6 months, whereas longer treatment
… [12] [13] Overall, these trials revealed that longer treatment with VKAs reduced the risk of …